Gland Pharma Limited has informed the Exchange about Annual General Meeting of the Company Scheduled to be held on August 28, 2025
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma's board approved audited financial results (standalone and consolidated) for Q4 and FY ended March 31, 2025, with statutory auditor Deloitte Haskins & Sells issuing an unmodified (clean) opinion on the consolidated financial statements. The board recommended a final dividend of Rs. 18 per share (1800%) on a face value of Rs. 1, subject to shareholder approval at the 47th AGM scheduled for August 28, 2025 (record date: August 14, 2025). The board also appointed M/s. RVR & Associates as Secretarial Auditors for a five-year term starting April 1, 2025, subject to shareholder approval. Additionally, several company policies (Material Subsidiaries, Related Party Transactions, Insider Trading, and Whistle Blower) were updated to align with recent SEBI regulatory amendments. Detailed revenue, profit, or margin figures were not disclosed in the body of this filing.
The clean (unmodified) audit opinion removes any near-term governance or accounting concerns, while the Rs. 18 final dividend signals strong capital returns to shareholders. The stock may see positive sentiment around the dividend record date, though the absence of headline financial numbers in this announcement means investors will need the full results/press release for earnings-related reactions.